Preview

Современная ревматология

Расширенный поиск

Значение циклофосфана в лечении интерстициального поражения легких у больных системной склеродермией(обзор литературы)

https://doi.org/10.14412/1996-7012-2010-597

Полный текст:

Аннотация

Интерстициальные заболевания легких (ИЗЛ) - частое проявление системной склеродермии (ССД), которое наряду с легочной артериальной гипертензией остается ведущей причиной смерти при данной нозологии. В настоящее время циклофосфан остается единственным иммуносупрессивным препаратом, рекомендованным EULAR для лечения ИЗЛ при ССД. В статье проанализированы работы, посвященные доказательству эффективности циклофосфана при ИЗЛ у пациентов с ССД. Рассмотрены схемы назначения и длительность терапии циклофосфаном, способы оценки его эффективности, влияние препарата на внелегочные проявления ССД. Сделано заключение о положительном, преимущественно стабилизирующем, влиянии циклофосфана на течение ИЗЛ при ССД

Об авторе

О. А. Конева



Литература

1. <div><p>Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы. М.: Медицина, 1993; 26.</p><p>Steen V.D., Conte C., Owens G.R. et al. Severe restrictive lung disease in systemic sclerosis. Arthr Rheum 1994; 37: 1283-9.</p><p>White B., Moore W.C., Wigley F.M. et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132(12): 947-54.</p><p>White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003; 29: 371-90.</p><p>Van Laar J.M., Stolk J., Tyndall A. Scleroderma lung. Pathogenesis, evaluation and current therapy. Drugs 2007; 67: 985-96.</p><p>Steen V.D., Conte C., Owens G.R. et al. Severe restrictive lung disease in systemic sclerosis. Arthr Rheum 1994; 37: 1283-9.</p><p>Hamilton R.F. Jr., Parsley E., Holian A. Alveolar macrophages from systemic sclerosis patients: evidence for IL-4 mediated pheno- type changes. Am J Physiol Lung cell Mil Physiol 2004; 286: 1202-9.</p><p>Wells A.U., Lorimer S., Majumdar S. et al. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells on lung interstitium. Eur Respir J 1995; 8: 266-71.</p><p>Behr J., Vogelmeier C., Beinert T. et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154: 400-6.</p><p>Southcott A.M., Jones K.P., Li D. et al. Interleukin-8: differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 1995; 151: 1604-12.</p><p>Corrin B., Butcher D., McAnulty B.J. et al. Immunohistochemical localization of transforming growth factor-B 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis ad other lung disoders. Histopathology 1994; 24: 145-50.</p><p>Steen V.D., Lanz J.K. Jr, Conte C. et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthr Rheum 1996 Jan; 39(1): 180.</p><p>Latsi P.I., Wells A.U. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003; 15: 748-55.</p><p>Tashkin D.P., Elashoff R., Clements P.G. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.</p><p>Mahler D.A., Weinberg D.H., Wells C.K. et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-8.</p><p>Davas E.M., Peppas C., Maragou M. et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheum 1999; 18(6): 455-61.</p><p>Hoyles R.K., Ellis R.W., Wellsbury J. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthr Rheum 2006; 12(54): 3962-70.</p><p>American Thoracic Society. Surveillance for respiratory hazards in the occupational setting. Am Rev Respir Dis 1982; 126: 952-6.</p><p>Nadashkevich O., Davis P., Fritzler M. et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25(2): 205-12</p><p>Pakas I., Ioannidis J.P., Malagari K. et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29(2): 298-304.</p><p>Silver R.M., Warrick J.H., Kinsella M.B. et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20(5): 838-44.</p><p>Valentini G., Paone C., La Montagna G. et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006; 35(1): 35-8.</p><p>Beretta L., Caronni M., Raimondi M. et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 2007; 26(2): 168-72.</p><p>Airo P., Danieli E., Rossi M. et al. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase A. Clin Exp Rheumatol 2007; 25(2): 169-71.</p><p>Nannini C., West C.P., Ervin P.J. et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthr Res Ther 2008; 10(5): 124.</p><p>Kowal-Bielecka O., Landeve R., Avouac J. et al. EULAR recommendations for the treatment of systemic sclerosis a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68(5): 620-9.</p><p>Tzelepsis G.E., Plastiras S.C., Karadimitrakis S.P. et al. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease. Clin Exp Rheumatol 2007; 25(5): 734-9.</p><p>Galgunery M., Apras S., Ozbalkan Z. et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003 Oct; 22(4- 5): 289-94.</p><p>Varai G., Earle L., Jimenez S.A. et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25: 1325-9.</p><p>Schnabel A., Reuter M., Gross W.L. Intravenous puls cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular disease. Arthr Rheum 1998; 41: 1215-20.</p><p>Kowal-Bieleska O., Kowal K., Rojewska J. et al. Cyclophosphamide reduced neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 2005; 64: 1343-6.</p><p>Silver R.M., Miller K.S., Kinsella M.B. et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470-6.</p><p>Behr J., Vogelmeier C., Beinert T. et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154: 400-6.</p><p>Witt C., Borges A.C., John M.I. et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: Bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999; 58: 635-40.</p><p>Mittoo S., Wigley F.M., Wise R. et al. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. Arthr Reum 2007; 56(12): 4195-202.</p><p>Giacomelli R., Valentini G., Salsano F. et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-6.</p><p>Paone C., Chiarolanza I., Cuomo G. et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007; 25(4): 613-6.</p><p>Silver R.M., Warrick J.H., Kinsella M.B. et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. Rheumatol 1993; 20(5): 838-44.</p><p>Griffiths B., Miles S., Moss H. et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. Rheumatol 2002; 29(11): 2371-78.</p><p>Tashkin D.P., Elashoff R., Clements P. et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Med 2007; 176: 1026-43.</p><p>Yiannopoulos G., Pastromas V., Antonopoulos I. et al. Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007; 27(4): 357-61.</p><p>Airo P., Danieli E., Parrinello G. et al.Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004; 22(5): 551-2.</p><p>Griffiths B., Miles S., Moss H. et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29(11): 2371-8.</p><p>Clements P.J., Roth M.D., Elashoff R. et al. Scleroderma Lung Study Group. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007; 66(12): 1641-7.</p><p>Caramaschi P., Volpe A., Pieropan S. et al. Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. Clin Rheumatol 2008; 28(4): 391-5.</p><p>Apras S., Ertenli I., Ozbalkan Z. et al. Effect of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthr Reum 2003; 48(8): 2256-61.</p><p>Beretta L., Cappiello F., Barili M. et al. T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis. Clin Rheumatol 2007; 26(1): 88-91.</p><p>Calguneri M., Apras S., Ozbalkan Z. et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003; 22(4-5): 289-94.</p><p>Ostojic P., Damjanov N. Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy. Clin Rheumatol 2006; 25(6): 819-21.</p><p>D'Angelo S., Cuomo G., Paone C. et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study. Clin Rheumatol 2003; 22(6): 393-6.</p><p>Varai G., Earle L., Jimenez S.A. et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25(7): 1325-9.</p><p>Baker G.L., Kahl L.E., Zee B.C. et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long- term case-control follow-up study. Am J Med 1987; 83: 1-9.</p><p>Baltus J.A., Boersma J.W., Hartman A.P. et al. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: controlled retrospective follow-up. Ann Rheum Dis 1983; 42: 368-73.</p><p>Talar-Williams C., Hijazi Y.M., Walther M.M. et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegner granulomatosis. Ann Intern Med 1996; 124: 477-84.</p><p>McCune W.J., Fox D.A. Immunosupressive agents: biologic effects in vivo and in vitro. In: Kammer G.M., Tsocos G.C. Lupus: molecular and cellular pathogenesis. Totowa N.J.: Humana Press, 1999: 612-41.</p><p>Toledano C., Henegar C., Ilie D. et al. [Cardiopulmonary function before and after cyclophosphamide treatment in severe systemic sclerosis: comparison of monthly intravenous bolus and autologous haematopoietic stem cell transplantation] [Article in French] Med Interne 2005; 26(6): 444-52.</p></div><br />


Для цитирования:


Конева О.А. Значение циклофосфана в лечении интерстициального поражения легких у больных системной склеродермией(обзор литературы). Современная ревматология. 2010;4(2):18-25. https://doi.org/10.14412/1996-7012-2010-597

For citation:


Koneva O.A. IMPORTANCE OF CYCLOPHOSPHANUM IN THE TREATMENT OF INTERSTITIAL LUNG LESION IN PATIENTS WITH SCLERODERMA SYSTEMATICA (A REVIEW OF LITERATURE). Modern Rheumatology Journal. 2010;4(2):18-25. (In Russ.) https://doi.org/10.14412/1996-7012-2010-597

Просмотров: 359


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)